SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Morepen Laboratories - Quaterly Results

12 May 2025 Evaluate
A slight decline in the revenue of Rs. 3819.38 millions was seen for the March 2025 quarter as against Rs. 3926.00 millions during year-ago period.Net Profit of the company move down -70.19% to Rs. 119.11  millions from Rs. 399.59 millions  in the same quarter last year.A decline of 333.01 millions was observed in the OP in the quarter ended March 2025 from 601.22 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 3819.38 3926.00 -2.72 15545.35 15375.94 1.10 15545.35 15375.94 1.10
Other Income 31.42 39.86 -21.17 157.20 125.66 25.10 157.20 125.66 25.10
PBIDT 333.01 601.22 -44.61 1691.31 1743.84 -3.01 1691.31 1743.84 -3.01
Interest 37.43 7.28 414.15 71.03 35.09 102.42 71.03 35.09 102.42
PBDT 295.58 593.94 -50.23 1620.28 1708.75 -5.18 1620.28 1708.75 -5.18
Depreciation 122.54 66.88 83.22 244.42 219.00 11.61 244.42 219.00 11.61
PBT 173.04 527.06 -67.17 1375.86 1489.75 -7.64 1375.86 1489.75 -7.64
TAX 53.93 127.47 -57.69 360.10 380.40 -5.34 360.10 380.40 -5.34
Deferred Tax 47.27 -4.36 -1184.17 47.27 -4.36 -1184.17 47.27 -4.36 -1184.17
PAT 119.11 399.59 -70.19 1015.76 1109.35 -8.44 1015.76 1109.35 -8.44
Equity 1095.84 1022.27 7.20 1095.84 1022.27 7.20 1095.84 1022.27 7.20
PBIDTM(%) 8.72 15.31 -43.07 10.88 11.34 -4.07 10.88 11.34 -4.07

Morepen Laboratories Share Price

41.25 1.13 (2.82%)
15-Apr-2026 10:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.35
Dr. Reddys Lab 1217.25
Cipla 1222.60
Zydus Lifesciences 931.00
Lupin 2343.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×